We suggest that targeted depletion of CD11c+ cells associated with the islet vasculature may yield a therapeutic target to inhibit T cell trafficking to inflamed islets to prevent progression of T1D. The gene discussed is ITGAX; the disease is type 1 diabetes mellitus.